In this issue of Immunity, Zheng and coworkers present a strategy to create transplantation tolerance with three critical elements, the combined administration of rapamycin, an agonist IL-2/Fc, and an antagonist mutant IL-15/Fc cytolytic-fusion protein to inhibit cytopathic effects but retain negative regulatory T cells, to permit allograft retention in animal models.